Sangamo Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and a Favorable Safety Profile

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 21, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Bank of America Securities Conference Date: Wednesday, May 11 th at 3:00 p.m.